论文部分内容阅读
目的:探讨膈下逐瘀汤联合肝动脉化疗栓塞术(TACE)治疗原发性肝癌的临床效果,以期提高临床治疗水平。方法:选取2010年4月~2013年4月180例原发性肝癌患者为研究对象,分成2组,对照组90例,予TACE术治疗,观察组90例,加用膈下逐瘀汤治疗,观察治疗后在相关指标变化。结果:治疗后对照组提高率34.44%、总有效率78.78%;观察组提高率60%,总有效率90%,两组比较差异有统计学意义;两组治疗后在ALT、TBIL、GGT、AFP上较治疗前有明显下降,治疗后两组ALT、TBIL、GGT、AFP比较差异有统计学意义;在并发症上,对照组肝肾功能损害、白细胞减少、骨髓抑制、血小板减少、恶心呕吐、疲乏无力、腹胀腹痛发生率分别占31.11%、25.56%、15.56%、34.44%、64.44%、51.11%、40%,观察组肝肾功能损害、白细胞减少、骨髓抑制、血小板减少、恶心呕吐、疲乏无力、腹胀腹痛发生率分别为22.22%、16.67%、7.78%、22.22%、45.56%、25.56%、23.33%,两组比较差异有统计学意义。结论:膈下逐瘀汤联合TACE术治疗原发性肝癌临床效果显著,能降低并发症,提高生存质量。
Objective: To investigate the clinical effect of Gexia Zhuyu Decoction combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer in order to improve the clinical treatment. Methods: One hundred and eighty patients with primary liver cancer from April 2010 to April 2013 were selected and divided into two groups. The control group received 90 cases of TACE, and the observation group of 90 cases were treated with Gexia Zhuyu Decoction , Observe the changes in the relevant indicators after treatment. Results After treatment, the improvement rate of the control group was 34.44%, the total effective rate was 78.78%; the improvement rate of the observation group was 60% and the total effective rate was 90%. There was significant difference between the two groups after treatment. The ALT, TBIL, GGT, AFP significantly decreased compared with before treatment, after treatment, ALT, TBIL, GGT, AFP difference was statistically significant; in the complications, the control group, liver and kidney dysfunction, leukopenia, myelosuppression, thrombocytopenia, nausea and vomiting , 31.3%, 25.56%, 15.56%, 34.44%, 64.44%, 51.11%, 40% of abdominal pain, abdominal weakness, abdominal fatigue, abdominal pain, liver dysfunction, leukopenia, myelosuppression, thrombocytopenia, nausea and vomiting, The incidence of abdominal weakness and abdominal distension was 22.22%, 16.67%, 7.78%, 22.22%, 45.56%, 25.56% and 23.33% respectively. The difference between the two groups was statistically significant. Conclusion: The treatment of primary hepatocellular carcinoma with GXMT combined with TACE has significant clinical effect, which can reduce the complication and improve the quality of life.